Skip to main content
. Author manuscript; available in PMC: 2017 Dec 21.
Published in final edited form as: Cancer Causes Control. 2016 Oct 11;27(11):1403–1409. doi: 10.1007/s10552-016-0813-7

Table 2.

Hazard ratios and 95% CI for lifestyle factors and mortality risk among endometrial cancer survivors in NIH-AARP (n = 580)

Deaths/total n Model 1 HR (95% CI) Model 2 HR (95% CI) Model 3 HR (95% CI) Model 4 HR (95% CI)
BMI (kg/m2)
  18.5–<25 21/172 1.00 1.00 1.00 1.00
  25–<30 26/160 1.33 (0.75, 2.37) 1.19 (0.66, 2.14) 1.10 (0.61, 2.01) 0.98 (0.53, 1.81)
  30–<35 21/133 1.30 (0.71, 2.39) 1.11 (0.57, 2.16) 0.97 (0.49, 1.92) 0.89 (0.45, 1.79)
  35+ 23/115 2.26 (1.23, 4.12) 2.14 (1.08, 4.24) 1.83 (0.90, 3.71) 1.47 (0.71, 3.07)
  p-trend 0.021 0.057 0.172 0.404
MVPA (MET h/week)
  0 36/174 1.00 1.00 1.00 1.00
  0.1–<15 24/162 0.69 (0.42, 1.13) 0.83 (0.48, 1.45) 0.86 (0.49, 1.51) 0.93 (0.54, 1.62)
  15+ 31/244 0.70 (0.42, 1.15) 0.72 (0.43, 1.21) 0.74 (0.43, 1.24) 0.87 (0.40, 1.09)
  p-trend 0.042 0.220 0.345 0.721
TV time (h/day)
  <3 31/240 1.00 1.00 1.00 1.00
  3–4 25/182 0.94 (0.56, 1.60) 0.88 (0.51, 1.51) 1.25 (0.74, 2.10) 1.21 (0.70, 2.10)
  5+ 35/158 1.61 (0.97, 2.65) 1.46 (0.86, 2.46) 2.69 (1.28, 5.65) 2.28 (1.05, 4.95)
  p-trend 0.057 0.168 0.026 0.082

Model 1 was adjusted for the factor of interest only

Model 2 was additionally adjusted for age at diagnosis, tumor stage (localized, regional/distant), tumor grade (well, moderately, poorly differentiated), first course of treatment (yes/no for surgery, chemotherapy, and radiation), diabetes (yes/no), age at menarche (≤12, >12 years old), and hormone use at baseline (ever/never)

Model 3 was additionally adjusted for the other main exposures of interest (BMI, MVPA, and TV)

Model 4 was additionally adjusted for self-reported health status (excellent/very good, good, fair/poor)